title: Endocrine and clinical effects of myo-inositol administration in polycystic ovary syndrome. A randomized study.
abstract: OBJECTIVE
  To evaluate the effects the administration of myo-inositol (MYO) on hormonal parameters in a group of polycystic ovary syndrome (PCOS) patients.
  
  
  METHODS
  Controlled clinical study.
  
  
  METHODS
  PCOS patients in a clinical research environment.
  
  
  METHODS
  50 overweight PCOS patients were enrolled after informed consent.
  
  
  METHODS
  All patients underwent hormonal evaluations and an oral glucose tolerance test (OGTT) before and after 12 weeks of therapy (Group A (n¼10): MYO 2 g plus folic acid 200 mg every day; Group B (n¼10): folic acid 200 mg every day). Ultrasound examinations and Ferriman-Gallwey score were also performed.
  
  
  METHODS
  Plasma LH, FSH, PRL, E2, 17OHP, A, T, glucose, insulin, C peptide concentrations, BMI, HOMA index and glucose-to-insulin ratio.
  
  
  RESULTS
  After 12 weeks of MYO administration plasma LH, PRL, T, insulin levels and LH/FSH resulted significantly reduced. Insulin sensitivity, expressed as glucose-to-insulin ratio and HOMA index resulted significantly improved after 12 weeks of treatment. Menstrual cyclicity was restored in all amenorrheic and oligomenorrheic subjects. No changes occurred in the patients treated with folic acid.
  
  
  CONCLUSIONS
  MYO administration improves reproductive axis functioning in PCOS patients reducing the hyperinsulinemic state that affects LH secretion.
authors: Department of Reproductive Medicine and Child Development, Division of Obstetrics and Gynecology, University of Pisa, Pisa, Italy. paolo.artini@med.unipi.it
authors: P G
authors: PG
authors: Artini
authors: O M
authors: OM
authors: Di Berardino
authors: F
authors: F
authors: Papini
authors: A D
authors: AD
authors: Genazzani
authors: G
authors: G
authors: Simi
authors: M
authors: M
authors: Ruggiero
authors: V
authors: V
authors: Cela
mesh_terms: D001786:Blood Glucose; D015992:Body Mass Index; D002096:C-Peptide / Q000097:blood; D004359:Drug Therapy, Combination; D004958:Estradiol / Q000097:blood; D005260:Female; D005492:Folic Acid / Q000627:therapeutic use*; D005640:Follicle Stimulating Hormone / Q000097:blood; D005951:Glucose Tolerance Test; D006801:Humans; D007294:Inositol / Q000627:therapeutic use*; D007328:Insulin / Q000097:blood; D007333:Insulin Resistance; D007986:Luteinizing Hormone / Q000097:blood; D011085:Polycystic Ovary Syndrome / Q000097:blood / Q000188:drug therapy*; D011388:Prolactin / Q000097:blood; D013739:Testosterone / Q000097:blood; D016896:Treatment Outcome
chemical_list: D001786:Blood Glucose; D002096:C-Peptide; D007328:Insulin; D013739:Testosterone; D007294:Inositol; D004958:Estradiol; D011388:Prolactin; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone; D005492:Folic Acid